Home | Harrow, Inc.
Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability.
Harrow Announces Third Quarter 2025 Financial Results
In September 2025, Harrow announced the launch of Harrow Access for All (HAFA), expanding Harrow’s commitment to make it easier and more affordable for patients to access Harrow’s full …
Harrow Partners with Cencora to Launch “Harrow Cares” Program, …
Jan 27, 2025 · Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of …
Harrow Announces Second-Quarter 2025 Financial Results
Jun 30, 2025 · Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes.
Leadership | Harrow, Inc.
Prior to joining Harrow, he was Founder and Chief Executive Officer of LVMA Consulting, advising emerging biotech companies and top 10 global pharmaceutical organizations on commercial …
Products - Harrow, Inc.
Harrow has acquired global rights to MELT-300 and MELT-210, and contracted for the U.S. commercial rights to BYQLOVI™, BYOOVIZ®, and OPUVIZ™. These products will be added to this section once …
Harrow Launches Harrow Access for All (HAFA) | Harrow, Inc.
The HarrowAccess.com portal will offer access to Harrow’s portfolio of specialty, generic, and compounded ophthalmic medications and Harrow-affiliated partner products.
Contact | Harrow, Inc.
At Harrow, we’re passionate about making eyecare more innovative, accessible, and affordable for everyone. Whether you're an eyecare professional, a patient, or a current — or future — member of …
About | Harrow, Inc.
Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance …
Harrow to Acquire Melt Pharmaceuticals
Sep 26, 2025 · By re-joining Harrow, we gain the resources and expertise needed to accelerate our programs and bring MELT-300 closer to the patients and physicians who need it most.